Literature DB >> 33670247

Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication.

Kingshuk Panda1, Kalichamy Alagarasu1, Deepti Parashar1.   

Abstract

Dengue fever is one of the most common viral infections affecting humans. It is an expanding public health problem, particularly in tropical and subtropical regions. No effective vaccine or antiviral therapies against Dengue virus (DENV) infection are available. Therefore, there is a strong need to develop safe and effective therapeutic strategies that can reduce the burden and duration of hospitalizations due to this life-threatening disease. Oligonucleotide-based strategies are considered as an attractive means of inhibiting viral replication since oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The resultant targeted destruction of viral RNA interferes with viral replication without inducing any adverse effects on cellular processes. In this review, we elaborate the ribozymes, RNA interference, CRISPR, aptamer and morpholino strategies for the inhibition of DENV replication and discuss the challenges involved in utilizing such approaches.

Entities:  

Keywords:  RNA interference; antisense oligonucleotides; antiviral; dengue; ribozymes

Mesh:

Substances:

Year:  2021        PMID: 33670247      PMCID: PMC7918374          DOI: 10.3390/molecules26040956

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  111 in total

Review 1.  A brief history of RNAi: the silence of the genes.

Authors:  George L Sen; Helen M Blau
Journal:  FASEB J       Date:  2006-07       Impact factor: 5.191

Review 2.  RNAi mechanisms and applications.

Authors:  Daniel Kim; John Rossi
Journal:  Biotechniques       Date:  2008-04       Impact factor: 1.993

Review 3.  The potential of ribozymes as antiviral agents.

Authors:  G Sczakiel; W Nedbal
Journal:  Trends Microbiol       Date:  1995-06       Impact factor: 17.079

4.  Deciphering the Self-Cleavage Reaction Mechanism of Hairpin Ribozyme.

Authors:  Narendra Kumar; Dominik Marx
Journal:  J Phys Chem B       Date:  2020-06-10       Impact factor: 2.991

5.  PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice.

Authors:  Chiara Da Pieve; Elaine Blackshaw; Sotiris Missailidis; Alan C Perkins
Journal:  Bioconjug Chem       Date:  2012-06-25       Impact factor: 4.774

Review 6.  Ribozymes as therapeutic tools for genetic disease.

Authors:  L A Phylactou; M W Kilpatrick; M J Wood
Journal:  Hum Mol Genet       Date:  1998       Impact factor: 6.150

7.  Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals.

Authors:  Pierre-Yves Lozach; Laura Burleigh; Isabelle Staropoli; Erika Navarro-Sanchez; Julie Harriague; Jean-Louis Virelizier; Felix A Rey; Philippe Desprès; Fernando Arenzana-Seisdedos; Ali Amara
Journal:  J Biol Chem       Date:  2005-04-26       Impact factor: 5.157

Review 8.  Medicinal and Therapeutic Potential of Herbs and Plant Metabolites / Extracts Countering Viral Pathogens - Current Knowledge and Future Prospects.

Authors:  Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Ashok Munjal; Ruchi Tiwari; Rajneesh Rana; Sandip Kumar Khurana; Rifat Ullah Khan; Mahmoud Alagawany; Mayada Ragab Farag; Maryam Dadar; Sunil Kumar Joshi
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

9.  Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript.

Authors:  Nawwaf Kharma; Luc Varin; Aida Abu-Baker; Jonathan Ouellet; Sabrine Najeh; Mohammad-Reza Ehdaeivand; Gabriel Belmonte; Anas Ambri; Guy Rouleau; Jonathan Perreault
Journal:  Nucleic Acids Res       Date:  2015-11-02       Impact factor: 16.971

10.  Overexpression of miR-484 and miR-744 in Vero cells alters Dengue virus replication.

Authors:  Juan Camilo Castrillón-Betancur; Silvio Urcuqui-Inchima
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-03-02       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.